title: [Reversal of neuromuscular blockade and complications of remaining blocking effect].
abstract: We Japanese anesthesiologists can now use rocuronium as well as vecuronium. Although the onset of rocuronium is more rapid, the non-depolarizing neuromuscular blocking (NMB) agent has similar characteristics of duration and recovery compared to vecuronium. Reversal of NMB is therefore essential to recover patients safely. Conventional standard of reversal of NMB [train of four (TOF) >0.7] is not enough to have sufficient vital capacity and inspiratory force, resulting in pulmonary regurgitation or atelectasis. Even though the reversal of NMB cannot sufficiently be completed by anti-cholinesterase (ChE) agents such as neostigmine, it is needed to reverse the NMB because of their late spontaneous recovery. We also have to take care of patients with neuromusclar diseases such as Duchenne-type muscle dystrophy, when we use anti-ChE agents. Sugammadex is a novel and unique compound designed as an antagonist of rocuronium and possibly other steroid NMB agents. Sugammadex exerts its effect by forming very tight water-soluble complexes at a 1 : 1 ratio with steroid NMB agents (rocuronium>vecuronium>>pancuronium). PhaseIII trials in Japan as well as Europe and the US have just been finished, and it is expected to be used clinically in the near future.
authors.affiliation: Department of Anesthesiology, Sapporo Medical University School of Medicine, Sapporo 060-8543.
authors.forename: Junpei
authors.initials: J
authors.lastname: Ohsone
authors.forename: Michiaki
authors.initials: M
authors.lastname: Yamakage
authors.forename: Takeshi
authors.initials: T
authors.lastname: Murouchi
mesh_terms: D000732:Androstanols / Q000009:adverse effects / Q000037:antagonists & inhibitors; D000762:Anesthesia Recovery Period; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D009388:Neostigmine / Q000008:administration & dosage / Q000494:pharmacology*; D009466:Neuromuscular Blocking Agents / Q000009:adverse effects* / Q000037:antagonists & inhibitors*; D009468:Neuromuscular Diseases; D010197:Pancuronium / Q000009:adverse effects / Q000037:antagonists & inhibitors; D000077123:Rocuronium; D000077122:Sugammadex; D014673:Vecuronium Bromide / Q000009:adverse effects / Q000037:antagonists & inhibitors; D047408:gamma-Cyclodextrins / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D000732:Androstanols; D002800:Cholinesterase Inhibitors; D009466:Neuromuscular Blocking Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D009388:Neostigmine; D014673:Vecuronium Bromide; D010197:Pancuronium; D000077123:Rocuronium